AstraZeneca strikes $700m deal with Dublin-based Actavis

Drugs giant AstraZeneca is to boost its portfolio with the acquisition of a branded respiratory drug business for up to US $700m (€613m).

AstraZeneca strikes $700m deal with Dublin-based Actavis

Drugs giant AstraZeneca is to boost its portfolio with the acquisition of a branded respiratory drug business for up to US $700m (€613m).

The agreement with Dublin-based rival Actavis to buy its respiratory business in North America includes the purchase of inhalation powder Tudorza Pressair, used by sufferers of chronic bronchitis.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited